European Commission logo
Deutsch Deutsch
CORDIS - Forschungsergebnisse der EU
CORDIS
Inhalt archiviert am 2024-05-24

Molecular mechanisms of disease progression and renoprotective pharmacotherapy in children with chronic renal failure

Ziel

ACE inhibitors are renoprotective in adults with chronic renal failure (CRF), but of unproven usefulness in children. In a randomised trial in 350 CRF children we will address if ACE inhibition is efficacious in slowing CRF progression in acquired and congenital nephropathies, if progression can be additionally influenced by intensified antihypertensive treatment achieving low-normal blood pressure, and which factors determine CRF progression and/or its susceptibility to ACE inhibition. Potential effects of renin-angiotensin system and PAI-l gene polymorphisms, mutations in genes defining glomerular structure or causing renal hypo/dysplasia, renal endothelnr-l turnover, plasma homocysteine and apolipoprotein phenotypes will be assessed. The cardiovascular consequences of childhood-onset CRF and renoprotective pharmacotherapy will be addressed by carotid ultrasound, echocardiography and 24-hour blood pressure monitoring.

Wissenschaftliches Gebiet

Programm/Programme

Thema/Themen

Aufforderung zur Vorschlagseinreichung

Data not available

Finanzierungsplan

CSC - Cost-sharing contracts

Koordinator

UNIVERSITAETSKLINIKUM HEIDELBERG
EU-Beitrag
Keine Daten
Adresse
Im Neuenheimer Feld 150
69115 HEIDELBERG
Deutschland

Auf der Karte ansehen
Gesamtkosten
Keine Daten

Beteiligte (27)

Diese Seite teilen

Herunterladen

Letzte Aktualisierung: 9 Dezember 2005

Mein Booklet

Permalink: https://cordis.europa.eu/project/id/QLG1-CT-2002-00908/de

European Union, 2024